They've barely dented on-label L sales, generic or brand - what makes you think they're suddenly going to capture a huge number of the ANCHOR population if they get approval? They may eventually, but it ain't gonna happen overnight, not with only a couple hundred sales reps and no advertising.
Let's face it - the company was set up for a BO on ANCHOR approval, not to continue as a biotech - and I expect many of us bought the stock in anticipation of that occurring. Now management has a horrible rep, and rightly so, stock is damaged as a result, investors will be skeptical until they see real revenues coming in. That's why I claim even ANCHOR approval doesn't blast this skywards - the starting pps is just too low now.
How did Generic Lovaza jump to 70K scripts per week? Surely not a sales force full court press.
We have a superior product and it costs less than Generic Lovaza.
It is a national health care failure to have generic Lovaza selling more scripts than Vascepa.
It isn't about sales forces, it is about insurance formularies giving precedence to an inferior expensive product and the MDs who fail to comprehend the potentially harmful adverse effects of generic lovaza.
Market Data 
Markets 
AI
